Shots:

• REGEN-COV neutralizes the SARS-CoV-2 B.1.1.7 variants- identified in the UK & SA. The data was included in a bioRxiv paper and submitted for peer-reviewed publication on the changing resistance of SARS-CoV-2 variants to Ab neutralization
• REGEN-COV retained its neutralizing capability against the B.1.1.7 variant. The Ab cocktails also retained its potency against the B.1.351 variant; imdevimab retained its potency against it while casirivimab potency was reduced
• Additionally- the Brazil variant (1.1.248) have the same receptor binding domain mutations as the B.1.351- thus REGEN-COV is expected to remain similarly potent. Regeneron is conducting additional research against this strain

 ­ Ref: PRNewswire | Image: Regeneron